Newbury Pharmaceuticals AB

Research Newbury Pharmaceuticals AB (NEWBRY) on Bullrun: market cap SEK 83.29M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is SEK 83.29M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025SEK 38.04M-SEK 21.54Mn/a39.0%n/aSEK 7.92Mn/aSEK 35.85M
FY2024SEK 24.61M-SEK 21.78Mn/a49.9%n/aSEK 19.43Mn/aSEK 46.77M
FY2023SEK 11.17M-SEK 19.42Mn/a43.5%n/aSEK 8.53Mn/an/a
FY2022SEK 7.23M-SEK 14.68Mn/a45.4%n/aSEK 33.33Mn/an/a

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-23SEK 83.29Mn/an/an/a

About Newbury Pharmaceuticals AB

Newbury Pharmaceuticals AB (publ) operates as hybrid pharmaceutical company in Sweden and the Scandinavian market. It offers oncology, rare diseases, neurology, and other treatment products. Newbury Pharmaceuticals AB (publ) was incorporated in 2020 and is based in Lund, Sweden.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Newbury Pharmaceuticals AB's market cap?

Newbury Pharmaceuticals AB's market capitalization is SEK 83.29M.

What does Newbury Pharmaceuticals AB do?

Newbury Pharmaceuticals AB (publ) operates as hybrid pharmaceutical company in Sweden and the Scandinavian market. It offers oncology, rare diseases, neurology, and other treatment products. Newbury Pharmaceuticals AB (publ) was incorporated in 2020 and is based in Lund, Sweden.